Abstract Number: PB0716
Meeting: ISTH 2020 Congress
Background: The disease, known as metabolic syndrome (МS), is often accompanied by thrombotic conditions caused by hyperproduction of the coagulation factor FXIII and the acute phase protein fibrinogen. The increase in fibrinogen levels, leading to increased clot density, and increased FXIII activity, enhancing the clot mechanical strength, the result lead to the slowing of fibrinolysis. Previously, the ability of short glyproline family peptides to influence the coagulation factors activity in health rats was established.
Aims: To evaluate the treatment effects of glyproline peptides RKKRPGP and KRKPGP on the fibrinogen levels and the FXIII activity in animals with experimental MS.
Methods: The experimental MS was reproduced on adult male Wistar rats, which were kept on high-calorie diet (130% of the normal caloric content) for 6 weeks. At the 43rd day of diet, MS rats were treated with peptides either RKKRPGP or KRKPGP (0.1 mg/kg, intranasally, once daily, 7 days). Control (untreated MC rats) and healthy animals received 0.85% saline. In blood samples obtained on the 50th and 57th days, the fibrinogen level and FXIII activity were determined. All procedures were carried out in accordance with international bioethics principles.
Results: RKKRPGP and KRKPGP-treatment led to a decrease in the FXIII activity (by 41 and 55% vs. control, respectively). The reduced FXIII activity (75 and 79% of the MS control), corresponding to the values of healthy animals, was maintained a week after treatment. At the 50th day of the experiment, a significant decrease in the fibrinogen concentration was found only after KRKPGP-treatment (71% vs. control), but not a week after treatment with both peptides (57th day).
Conclusions: So, the peptides RKKRPGP and KRKPGP affect the fibrinolysis processes in metabolic disorders due to their ability to reduce the FXIII activity and fibrinogen levels (only KRKPGP), which can be useful in the fight against MS complications.
To cite this abstract in AMA style:Shubina T, Obergan T. Effects of Lysine-Containing Peptides Treatment on FXIII Activity and Fibrinogen Level of Metabolic Disorders [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/effects-of-lysine-containing-peptides-treatment-on-fxiii-activity-and-fibrinogen-level-of-metabolic-disorders/. Accessed May 6, 2021.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/effects-of-lysine-containing-peptides-treatment-on-fxiii-activity-and-fibrinogen-level-of-metabolic-disorders/